The global market for human antifungal therapeutics was valued at $9.8 billion in 2009 and is expected to increase at a compound annual growth rate (CAGR) of approximately 3.8% to reach $11.3 billion in 2014.
The Latin and South American region will experience the greatest compound annual growth rate (CAGR) of 8.3%, reflecting an increase in revenues from $637 million in 2009 to $949 million in 2014.
In North America, human antifungal therapeutics were valued at $3.9 billion in 2009 and are expected to increase at a 0.7% compound annual growth rate (CAGR) to reach $4 billion in 2014.
STUDY GOALS AND OBJECTIVES
BCC’s goal in conducting this study was to determine the current status of the global human antifungal market and assess its growth potential over the 5-year period from 2009 to 2014. The focus of this report is human therapeutics, including approved therapeutics with a heavy focus on therapeutics in early development. These new molecular and biological entities are from both traditional pharmaceutical sources and include naturally derived, synthetic chemicals, biological sources, as well as the “herbal natural folk medicine” marketplace. If an approved or well-known medicine is being studied in combination with another molecular entity, it is considered a “new therapy” and often has been included for review. New drug and patent applications are presented as the study focuses on new methods of drug administration, drug clinical trials, discovery, and development.
It should be noted that there is a strong emphasis on early research, given the critical need for new and more effective medicines. Given this, BCC is including a section of medicines that are intended for human utilization that are in the preclinical (animal) models of testing, and information on new and novel in-vitro therapies. Greater than 98% of medicines at the preclinical level are terminated prior to their utilization in humans, and the research in this area is vast. We are limiting this research to therapies that depict a positive result or represent a very rare and novel approach worthy of further review from R&D groups.
Our key objective in this report is to present an in-depth analysis of the current human antifungal market and explore its future direction. In the last 3 years, there has been a vast increase in the number of patent applications filed in this area. Between 1990 and 1999, there were six U.S. patents granted given the evolution of drug resistance and an increasing mortality rate.,
REASONS FOR DOING THIS STUDY
Fungi are highly resistant microbiological eukaryotic microorganisms. In other words, they are becoming drug-resistant to the approved compounds and some therapies later in clinical development. The therapies are designed to eradicate them through the various antifungal mechanisms of action, such as disrupting reproductive capabilities, destroying cell walls, or modifying fungal DNA and cell functioning. It is a given fact that infestations in humans, animals, plants, and the environment are on the rise, with many having lethal consequences in both the immunocompetent and the immunocompromised. As such, BCC was particularly interested in examining the antifungal market growth of developing products depicting efficacy. We are including data regarding the market shift for those products that are now relegated to over-the-counter (OTC) status previously having only been provided by prescription, and to identify new antifungal research, development, new drug applications, and novel approaches to the market.
Previously, BCC examined the antifungal market in its 2003 report, PHM029A The Market for Antifungal Drugs and in PHM029B Global Markets for Antifungal Agents. Due to the rapidly changing market, BCC chose to reexamine the marketplace through another analysis and project its new growth potential. Additionally, PHM029Afocused only on human fungal diseases and associated antifungals; PHM029B incorporated the marketplace for antifungals in the veterinary, agricultural, and environmental industries; this report, PHM029C, is focused on human therapeutics with an intensive focus on human therapeutics in the developmental pipeline.
This report was prepared as a study of the global antifungal marketplace based on fungal infections and infestations with a focus on human therapeutics. Information is presented on the antifungal industry in general, pharmaceuticals and chemical agents, new technology within the market, new and novel drug applications, market-related issues, and in many cases actual revenue is given for the period of 2007 to 2009, with projections of trends and compound annual growth rates (CAGRs) through 2014.
This study will be of significant interest to hospitals, pharmacies, pharmaceutical companies, biopharmaceutical researchers, pharmaceutical company marketing executives, contract research organizations (CROs), chemists, physicians, nurses, physician assistants, pharmaceutical directors, product managers and representatives, all manner of institutional directors ranging from nursing homes and schools to those in long-term-care situations, both public and private. It will also be of interest to biologists and those interested in the field of mycology.
SCOPE OF REPORT
This study examines human applications both marketed and in the development of antifungal technologies. In an extensive analysis, BCC analyzes each market segment, presents its current market status, and presents various forecasts for growth over the next 5 years. Other factors such as Food and Drug Administration (FDA) restrictions, government legislation, fungal resistance, and changes in consumerism such as a greater demand for OTC medications and/or natural and alternative remedies are also highlighted. Our financial and sales analysis focuses on the available figures from 2007 to 2009, with estimates for the years 2009 to 2014, including CAGR as a percentage.
Through an extensive industry survey, inclusive of online database searches of industry specific data sources coupled with financial, trade, government, and marketing database sources as well as interviews via correspondence or telephone with independent sources comprising companies, government agencies, and academic experts, BCC was able to compile data to present our analysis of the antifungal market, by market segment.
Of the companies and agencies surveyed, the majority were pharmaceutical or compound manufacturers. Additional information was supplied by known industry or trade sources.
Michael Delander is a biotechnology research consultant with more than 15 years of research experience. Michael has been consulting with venture capital (VC) based start-ups and larger industry alike since 2003, and has focused on in-depth research in a wide range of medical therapeutics in early development. His key published work is located in national and international organizations, including the National Library of Medicine, numerous Ivy League libraries, and numerous University of California locations.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at
www.bccresearch.com, enables readers to:
Examine BCC’s complete catalog of Market Research Reports and place direct orders
Subscribe to any of BCC’s many industry newsletters
Read announcements of recently published reports and newly launched newsletters
Register for BCC’s well-known conferences
Request additional information on any BCC product
Take advantage of special offers.
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute medical, managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use. Of note, the data selected in the document through 2009 is the most complete figures available as of the third quarter.
Published - Mar-2007|
Analyst - Danielle West|
Code - PHM029B
The total global market for antifungal agents was worth more than $13.5 billion in 2005 and declined to just under $12.2 billion in 2006. The market will continue to dip through 2007 to $11.9 billion but will recover to more than $14.7 billion, a compound annual growth rate (CAGR) of 2.8%
Antifungal agents for humans held the highest share of the market through the forecast period. In 2007 they will be worth more than $11.2 billion and will reach nearly $14 billion by 2012, a CAGR of 4.5%.
Trends for fungal infections among animals are still a major concern as industry trends indicate. The market for animal antifungals will be worth $107 million in 2007 and will reach $110.7 million by 2012, a CAGR of 3.5%.
Published - Apr-2003|
Analyst - Lynn Gray|
Code - PHM029A
The market for antifungal drugs is estimated at $5.9 billion in 2002, including both prescription and OTC products.
Overall, the market is projected to rise at an average annual growth rate (AAGR) of 7.9% through 2007 to $8.7 billion.
There are about 30 branded prescription systemic and topical antifungal agents on the market and several dozen over-the-counter branded and generic topical antifungal products.
Products from several entirely new categories of compounds will be introduced during the forecast period.
More than a dozen new prescription products are in clinical development and will contribute to the growth in this market.
Need a custom data table, graph or complete report? Tell us more.
BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth opportunities, market sizing, technologies, applications, supply chains and companies with the singular goal of helping you make informed business decisions, free of noise and hype.
Thank you for your interest in BCC Research. You will be added to our mailing list.